Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Split-Luciferase-Based Trimer Formation Assay as a High-throughput Screening Platform for Therapeutics in Alport Syndrome.
Omachi K, Kamura M, Teramoto K, Kojima H, Yokota T, Kaseda S, Kuwazuru J, Fukuda R, Koyama K, Matsuyama S, Motomura K, Shuto T, Suico MA, Kai H. Omachi K, et al. Among authors: yokota t. Cell Chem Biol. 2018 May 17;25(5):634-643.e4. doi: 10.1016/j.chembiol.2018.02.003. Epub 2018 Mar 8. Cell Chem Biol. 2018. PMID: 29526710 Free article.
Podocyte p53 Limits the Severity of Experimental Alport Syndrome.
Fukuda R, Suico MA, Kai Y, Omachi K, Motomura K, Koga T, Komohara Y, Koyama K, Yokota T, Taura M, Shuto T, Kai H. Fukuda R, et al. Among authors: yokota t. J Am Soc Nephrol. 2016 Jan;27(1):144-57. doi: 10.1681/ASN.2014111109. Epub 2015 May 12. J Am Soc Nephrol. 2016. PMID: 25967122 Free PMC article.
Metformin ameliorates the severity of experimental Alport syndrome.
Omachi K, Kaseda S, Yokota T, Kamura M, Teramoto K, Kuwazuru J, Kojima H, Nohara H, Koyama K, Ohtsuki S, Misumi S, Takeo T, Nakagata N, Li JD, Shuto T, Suico MA, Miner JH, Kai H. Omachi K, et al. Among authors: yokota t. Sci Rep. 2021 Mar 29;11(1):7053. doi: 10.1038/s41598-021-86109-1. Sci Rep. 2021. PMID: 33782421 Free PMC article.
Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
Rodón J, Damian S, Furqan M, García-Donas J, Imai H, Italiano A, Spanggaard I, Ueno M, Yokota T, Veronese ML, Oliveira N, Li X, Gilmartin A, Schaffer M, Goyal L. Rodón J, et al. Among authors: yokota t. Nat Med. 2024 May 24. doi: 10.1038/s41591-024-03072-w. Online ahead of print. Nat Med. 2024. PMID: 38789647 No abstract available.
2,326 results